Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | LDHB | P07195 | 1/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86396 | 0.80 | KDM4E (0.52) | ALDH1A1TSHRKDM4ETDP1GAA | |
| SCHEMBL17495564 | 0.80 | KDM4E (0.52) | ALDH1A1TSHRKDM4ETDP1GAA | |
| SCHEMBL28611785 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRKDM4ETDP1GAA | |
| SCHEMBL13637612 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRKDM4ETDP1GAA | |
| SCHEMBL13524319 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRKDM4ETDP1GAA | |
| SCHEMBL11805964 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRKDM4ETDP1GAA | |
| SCHEMBL1355720 | 0.78 | MAPT (0.39) | ALDH1A1TDP1HTTHPGDMAPT | |
| SCHEMBL23828689 | 0.77 | ALDH1A1 (0.48) | ALDH1A1TSHRKDM4ETDP1GAA | |
| Methane SCHEMBL16742564 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TSHRKDM4ETDP1GAA | |
| SCHEMBL26696157 | 0.75 | ALDH1A1 (0.47) | ALDH1A1TSHRKDM4ETDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112625014-B | Method for preparing 2, 5-furan diformyl chloride from 5-chloromethyl furfural | 国网安徽省电力有限公司电力科学研究院 | 2023-05-23 | — | — | CN | disclosed |
| CN-112552269-A | Method for synthesizing 2, 5-furan diformyl chloride in one step | 国网安徽省电力有限公司电力科学研究院 | 2021-03-26 | — | — | CN | disclosed |
| CN-105658612-A | Methods and compounds for producing nylon 6,6 | 英派尔科技开发有限公司 | 2016-06-08 | — | — | CN | disclosed |
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| CN-1960981-A | As histamine H3Non-imidazole heterocyclic compounds as receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-09 | — | — | CN | disclosed |
| EP-1771432-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2005096734-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | ALDH1A1 2417/4885TSHR 655/4885KDM4E 845/4885 |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | ALDH1A1 2417/4885TSHR 655/4885KDM4E 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.